Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Xspray Pharma AB (publ)
AB
Active
Org 5566493671
Scheeles Väg 2, 171 65
Solna
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2003 · 22 years old
25 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Xspray Pharma AB (publ)
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2020: 0M
0M
2020
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
EBITDA
SEK millions
0M
-89M
-179M
-268M
-357M
2020: -53M
-53M
2020
2021: -98M (-85% vs 2020)
-98M
-85%
2021
2022: -134M (-37% vs 2021)
-134M
-37%
2022
2023: -183M (-37% vs 2022)
-183M
-37%
2023
2024: -287M (-57% vs 2023)
-287M
-57%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
0
0
0
0
0
Staff expenses
—
—
—
—
—
EBITDA
−287 273
−182 769
−133 622
−98 050
−53 381
Depreciation & amort.
—
−0
−0
−0
−0
EBIT
−287 273
−182 769
−133 622
−98 050
−53 381
Net financials
−1 375
989
605
930
1 043
Profit before tax
−286 719
−181 781
−133 017
−97 116
−52 333
Tax
−0
−0
−0
−0
−0
Net profit
−286 719
−181 781
−133 017
−97 116
−52 333
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
760 293
726 507
581 592
619 305
600 472
Equity
618 052
689 771
554 306
591 386
582 640
Long-term debt
0
0
0
0
0
Short-term debt
142 241
36 736
27 285
27 919
17 832
Total debt
142 241
36 736
27 285
27 919
17 832
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
81,3 %
This company
38,2 %
Market median
This company
Market median
113% above market
2020
2024
Return on equity
−46,4 %
This company
18,4 %
Market median
This company
Market median
352% below market
2020
2024
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2020
2024
Debt / equity
0,23×
This company
0,62×
Market median
This company
Market median
63% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Xspray Pharma AB (publ)
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
